Spyre Therapeutics vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Spyre Therapeutics Inc. (SYRE)

Q3 202629 Jun – 17 Sep 2026

▲3▼1

Spyre's IBD pipeline hits key goals, but RA setback and combo wait cap gains

SPY003 Phase 2 success completes IBD monotherapy trio SPY003 hit its Phase 2 primary endpoint, completing proof-of-concept for all three IBD monotherapy molecules. This validates the building blocks of Spyre's combination strategy, boosting confidence in future combo data and supporting the stock's premium valuation.
This is the latest major pipeline win that directly drives investor optimism about Spyre's core IBD strategy.
Spyre drops SPY072 as standalone RA treatment despite positive data Spyre decided not to develop SPY072 as a standalone rheumatoid arthritis treatment even though it showed positive statistical results. This removes a potential near-term revenue driver and raises questions about the drug's commercial path, weighing on the stock.
This is a new negative event that changes the outlook for one of Spyre's key pipeline assets.
New HS study expands combination approach beyond IBD Spyre launched the Phase 2 SKYLIGHT study of SPY772 in hidradenitis suppurativa, testing SPY072 plus bimekizumab. This broadens the pipeline into a new disease area, but topline data are not expected until late 2027 or early 2028, so it's a longer-term positive.
This is a new pipeline expansion that shows Spyre's strategy can extend beyond IBD, supporting long-term growth expectations.
Strong cash runway funds operations into 2H 2029 Spyre ended Q2 with $1.15 billion in cash, helped by a $435 million April stock offering and a $40 million milestone gain. This funds operations into the second half of 2029, reducing near-term financing risk and allowing focus on data readouts.
A strong balance sheet is a key support for a clinical-stage biotech with no revenue, directly affecting its ability to fund pipeline development.

August 202629 Jun – 17 Sep 2026

▲3▼1

Spyre's IBD pipeline hits key goals, but RA setback and combo wait cap gains

SPY003 Phase 2 success completes IBD monotherapy trio SPY003 hit its Phase 2 primary endpoint, completing proof-of-concept for all three IBD monotherapy molecules. This validates the building blocks of Spyre's combination strategy, boosting confidence in future combo data and supporting the stock's premium valuation.
This is the latest major pipeline win that directly drives investor optimism about Spyre's core IBD strategy.
Spyre drops SPY072 as standalone RA treatment despite positive data Spyre decided not to develop SPY072 as a standalone rheumatoid arthritis treatment even though it showed positive statistical results. This removes a potential near-term revenue driver and raises questions about the drug's commercial path, weighing on the stock.
This is a new negative event that changes the outlook for one of Spyre's key pipeline assets.
New HS study expands combination approach beyond IBD Spyre launched the Phase 2 SKYLIGHT study of SPY772 in hidradenitis suppurativa, testing SPY072 plus bimekizumab. This broadens the pipeline into a new disease area, but topline data are not expected until late 2027 or early 2028, so it's a longer-term positive.
This is a new pipeline expansion that shows Spyre's strategy can extend beyond IBD, supporting long-term growth expectations.
Strong cash runway funds operations into 2H 2029 Spyre ended Q2 with $1.15 billion in cash, helped by a $435 million April stock offering and a $40 million milestone gain. This funds operations into the second half of 2029, reducing near-term financing risk and allowing focus on data readouts.
A strong balance sheet is a key support for a clinical-stage biotech with no revenue, directly affecting its ability to fund pipeline development.

Latest29 Jun – 17 Sep 2026

▲3▼1

Spyre's IBD pipeline hits key goals, but RA setback and combo wait cap gains

SPY003 Phase 2 success completes IBD monotherapy trio SPY003 hit its Phase 2 primary endpoint, completing proof-of-concept for all three IBD monotherapy molecules. This validates the building blocks of Spyre's combination strategy, boosting confidence in future combo data and supporting the stock's premium valuation.
This is the latest major pipeline win that directly drives investor optimism about Spyre's core IBD strategy.
Spyre drops SPY072 as standalone RA treatment despite positive data Spyre decided not to develop SPY072 as a standalone rheumatoid arthritis treatment even though it showed positive statistical results. This removes a potential near-term revenue driver and raises questions about the drug's commercial path, weighing on the stock.
This is a new negative event that changes the outlook for one of Spyre's key pipeline assets.
New HS study expands combination approach beyond IBD Spyre launched the Phase 2 SKYLIGHT study of SPY772 in hidradenitis suppurativa, testing SPY072 plus bimekizumab. This broadens the pipeline into a new disease area, but topline data are not expected until late 2027 or early 2028, so it's a longer-term positive.
This is a new pipeline expansion that shows Spyre's strategy can extend beyond IBD, supporting long-term growth expectations.
Strong cash runway funds operations into 2H 2029 Spyre ended Q2 with $1.15 billion in cash, helped by a $435 million April stock offering and a $40 million milestone gain. This funds operations into the second half of 2029, reducing near-term financing risk and allowing focus on data readouts.
A strong balance sheet is a key support for a clinical-stage biotech with no revenue, directly affecting its ability to fund pipeline development.

Abcellera Biologics Inc (ABCL)

Q3 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest17 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.